Guggenheim Capital LLC Krystal Biotech, Inc. Transaction History
Guggenheim Capital LLC
- $14 Billion
- Q3 2024
A detailed history of Guggenheim Capital LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 3,935 shares of KRYS stock, worth $634,715. This represents 0.01% of its overall portfolio holdings.
Number of Shares
3,935
Previous 4,709
16.44%
Holding current value
$634,715
Previous $864,000
17.25%
% of portfolio
0.01%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding KRYS
# of Institutions
304Shares Held
24.3MCall Options Held
483KPut Options Held
364K-
Black Rock Inc. New York, NY3.95MShares$637 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.85MShares$460 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.62MShares$423 Million7.18% of portfolio
-
State Street Corp Boston, MA1.45MShares$234 Million0.01% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA988KShares$159 Million9.67% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.14B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...